Cabergoline in severe ectopic or occult Cushing’s syndrome

Context Cabergoline has been shown to have some effect in the treatment of moderate Cushing’s disease, but its effectiveness in Cushing’s syndrome of ectopic or occult origin remains to be investigated. Case series In this case series, cabergoline was used in combination with steroidogenesis inhibitors in nine patients with severe Cushing’s syndrome of ectopic or occult origin. Cabergoline’s effectiveness enabled rapid withdrawal of the steroidogenesis inhibitors and long-term control of the hypercortisolism in three of the cases. Review of the literature In the literature, we found only 11 cases of ectopic or occult Cushing’s syndrome treated with dopamine receptor agonists, alone or in combination. Yet of these 11 cases, 10 responded. Conclusions Although limited, the existing experience highlights the potential value of cabergoline in the treatment of ectopic or occult Cushing’s syndrome.

Correction of non-motor vegetative fluctuations with parkinson’s disease based on levodopa treatment

The influence of dopamine receptor agonists in the transdermal and oral forms of drugs and amantadine for a non-motor autonomic fluctuations of patients with different duration of the disease during the treatment of Parkinson's in a stable dose of levodopa were established. It was analysed, that the use of dopamine receptor agonists in the transdermal and oral forms of drugs reduce the frequency and duration of vegetative non-motor fluctuations of patients with Parkinson's disease. The use of amantadine sulphate has little effect in a decrease of non-motor autonomic fluctuations.